These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 39033778)

  • 1. Integrating single-cell RNA-seq to identify fibroblast-based molecular subtypes for predicting prognosis and therapeutic response in bladder cancer.
    Wang J; Tan Z; Huang Y; Li C; Zhan P; Wang H; Li H
    Aging (Albany NY); 2024 Jul; 16(14):11385-11408. PubMed ID: 39033778
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comprehensive analysis of scRNA-Seq and bulk RNA-Seq reveals dynamic changes in the tumor immune microenvironment of bladder cancer and establishes a prognostic model.
    Tan Z; Chen X; Zuo J; Fu S; Wang H; Wang J
    J Transl Med; 2023 Mar; 21(1):223. PubMed ID: 36973787
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of a tumor microenvironment-related seven-gene signature for predicting prognosis in bladder cancer.
    Wang Z; Tu L; Chen M; Tong S
    BMC Cancer; 2021 Jun; 21(1):692. PubMed ID: 34112144
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification and validation of a signature based on myofibroblastic cancer-associated fibroblast marker genes for predicting prognosis, immune infiltration, and therapeutic response in bladder cancer.
    Qin R; Ma X; Pu S; Shen C; Hu D; Liu C; Wang K; Wang Y
    Investig Clin Urol; 2024 May; 65(3):263-278. PubMed ID: 38714517
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune checkpoint gene signature assesses immune infiltration profiles in bladder cancer and identifies KRT23 as an immunotherapeutic target.
    Chen D; Cao H; Zheng X; Wang H; Han Z; Wang W
    BMC Cancer; 2024 Aug; 24(1):1024. PubMed ID: 39160525
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Integrating Bulk and Single-Cell RNA Sequencing Reveals Heterogeneity, Tumor Microenvironment, and Immunotherapeutic Efficacy Based on Sialylation-Related Genes in Bladder Cancer.
    Tan Z; Chen X; Zuo J; Fu S; Wang J; Wang H
    J Inflamm Res; 2023; 16():3399-3417. PubMed ID: 37600224
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Scoring System Based on RNA Modification Writer-Related Genes to Predict Overall Survival and Therapeutic Response in Bladder Cancer.
    Zhang P; Liu Z; Wang D; Li Y; Xing Y; Xiao Y
    Front Immunol; 2021; 12():724541. PubMed ID: 34512654
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Weighted gene co-expression network analysis can sort cancer-associated fibroblast-specific markers promoting bladder cancer progression.
    Liu B; Zhan Y; Chen X; Hu X; Wu B; Pan S
    J Cell Physiol; 2021 Feb; 236(2):1321-1331. PubMed ID: 32657439
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advancing bladder cancer management: development of a prognostic model and personalized therapy.
    Huang X; Du G; Yang Y; Su P; Chen S; Cai C; Huang T; Zeng Y; Tao Y; Tian D; Zhang N
    Front Immunol; 2024; 15():1430792. PubMed ID: 39104534
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single-cell and bulk RNA-sequence identified fibroblasts signature and CD8 + T-cell - fibroblast subtype predicting prognosis and immune therapeutic response of bladder cancer, based on machine learning: bioinformatics multi-omics study.
    Li J; Kong Z; Qi Y; Wang W; Su Q; Huang W; Zhang Z; Li S; Du E
    Int J Surg; 2024 Aug; 110(8):4911-4931. PubMed ID: 38759695
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Results from a real-world study: a novel glycosyltransferase risk score for prognosis, tumor microenvironment phenotypes and immunotherapy in bladder cancer.
    Liu R; Yang T; Huang J; Xiao Z; Liu J; Li Z; Tong S
    BMC Cancer; 2024 Aug; 24(1):947. PubMed ID: 39095785
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comprehensive analysis of scRNA-seq and bulk RNA-seq reveal the characteristics of disulfidptosis and a prognostic signature in BLCA.
    Deng H; Cheng F; Cheng S
    Aging (Albany NY); 2024 Mar; 16(6):5751-5771. PubMed ID: 38507521
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic Benefits and Prognostic Value of a Model Based on 7 Immune-associated Genes in Bladder Cancer.
    Cao M; Cao Y; Xue S; Zhang Q; Zhang H; Xue W
    Altern Ther Health Med; 2024 Apr; 30(4):130-138. PubMed ID: 38518167
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Novel TGF-β Risk Score Predicts the Clinical Outcomes and Tumour Microenvironment Phenotypes in Bladder Cancer.
    Liu Z; Qi T; Li X; Yao Y; Othmane B; Chen J; Zu X; Ou Z; Hu J
    Front Immunol; 2021; 12():791924. PubMed ID: 34975891
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cancer-associated fibroblast-derived gene signature discriminates distinct prognoses by integrated single-cell and bulk RNA-seq analyses in breast cancer.
    Fang Z; Han YL; Gao ZJ; Yao F
    Aging (Albany NY); 2024 May; 16(9):8279-8305. PubMed ID: 38728370
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of a prognostic index and screening of prognosis related genes based on an immunogenomic landscape analysis of bladder cancer.
    Qu G; Liu Z; Yang G; Xu Y; Xiang M; Tang C
    Aging (Albany NY); 2021 Apr; 13(8):12099-12112. PubMed ID: 33888644
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Construction of cancer- associated fibroblasts related risk signature based on single-cell RNA-seq and bulk RNA-seq data in bladder urothelial carcinoma.
    Liu Y; Jian J; Zhang Y; Wang L; Liu X; Chen Z
    Front Oncol; 2023; 13():1170893. PubMed ID: 37124542
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Integrated analysis of single-cell and bulk RNA-sequencing identifies a signature based on T-cell marker genes to predict prognosis and immunotherapy response in bladder cancer.
    Shi X; Dong A; Yang Y; Zheng G; Wang N; Yang C; Wang Y; Lu J; Jia X
    J Cancer Res Clin Oncol; 2023 Sep; 149(12):9733-9746. PubMed ID: 37244876
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Deciphering the immunological and prognostic features of bladder cancer through platinum-resistance-related genes analysis and identifying potential therapeutic target P4HB.
    Xiong S; Li S; Zeng J; Nie J; Liu T; Liu X; Chen L; Fu B; Deng J; Xu S
    Front Immunol; 2023; 14():1253586. PubMed ID: 37790935
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FGL2 as a predictive biomarker for prognosis and immunotherapy in bladder cancer.
    Huang Z; Wang Z; Xu C; Yan Y; Cao X; Zhang F; Shen B
    Int J Med Sci; 2024; 21(8):1447-1460. PubMed ID: 38903931
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.